Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoASPECT: Neoadjuvant Ivonescimab and Chemoimmunotherapy for Early-Stage TNBC
NCT07743632Phase 2Not yet recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Sep 2026
- Primary completion
- Dec 2032
01
Overview
Phase 2, open-label trial of ivonescimab in triple-negative breast cancer (TNBC) (2 cohorts), sponsored by University of Kansas Medical Center. Primary endpoint: Pathologic complete response. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07743632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743632.